Well I'd say there's a reason the "Clinuvel will be a household name by 2026" coincides with the expected FDA approval and launch of Scenesse for Vitiligo. Expansion in indication for use and additional clinical data will pave the way for greater access. But regardless, creams and lotions are far easier to get to the OTC market than injections and implants (I think Scenesse will eventually arrive to the consumer market though, as an implant will always be more effective)
See what is said in the Annual Report and/or AGM, I suspect we will get more info then.
I agree very strongly with the last point you make though, the rhetoric around sun exposure and protection is completely outdated and incorrect. Hopefully Clinuvel will spearhead the change
Well I'd say there's a reason the "Clinuvel will be a...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.10 |
Change
-0.010(0.07%) |
Mkt cap ! $705.8M | |||
| Open | High | Low | Value | Volume |
| $14.10 | $14.21 | $13.88 | $794.1K | 56.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $14.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.11 | 248 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| CUV (ASX) Chart |